Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
INTS Stock Forecast 2025-2026
$0.33
Current Price
$8.68M
Market Cap
Buy 3
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to INTS Price Targets
+1,401.5%
To High Target of $5.00
+1,026.1%
To Median Target of $3.75
+350.5%
To Low Target of $1.50
INTS Price Momentum
+17.9%
1 Week Change
+3.1%
1 Month Change
-93.5%
1 Year Change
-81.3%
Year-to-Date Change
-93.5%
From 52W High of $5.10
+28.1%
From 52W Low of $0.26
📊 TOP ANALYST CALLS
Did INTS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Intensity Therapeutics is one of their latest high-conviction picks.
Latest INTS Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, INTS has a bullish consensus with a median price target of $3.75 (ranging from $1.50 to $5.00). Currently trading at $0.33, the median forecast implies a 1,026.1% upside. This outlook is supported by 3 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Swayampakula Ramakanth at HC Wainwright & Co., projecting a 1,401.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INTS Analyst Ratings
3
Buy
2
Hold
0
Sell
INTS Price Target Range
Low
$1.50
Average
$3.75
High
$5.00
Current: $0.33
Latest INTS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INTS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 13, 2025 | Alliance Global Partners | James Molloy | Buy | Initiates | $8.50 |
| Nov 21, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $5.00 |
| Oct 31, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Initiates | $5.00 |
| Jul 11, 2024 | Benchmark | Robert Wasserman | Speculative Buy | Reiterates | $12.00 |
| May 16, 2024 | Benchmark | Robert Wasserman | Speculative Buy | Reiterates | $12.00 |
| Mar 21, 2024 | Benchmark | Robert Wasserman | Speculative Buy | Reiterates | $12.00 |
| Nov 14, 2023 | Benchmark | Robert Wasserman | Speculative Buy | Reiterates | $12.00 |
| Aug 24, 2023 | Benchmark | Robert Wasserman | Speculative Buy | Reiterates | $12.00 |
| Jul 18, 2023 | Benchmark | Robert Wasserman | Speculative Buy | Initiates | $12.00 |
Intensity Therapeutics Inc. (INTS) Competitors
The following stocks are similar to Intensity Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
INTS
Intensity Therapeutics
mkt cap
8.68M
Intensity Therapeutics Inc. (INTS) Financial Data
Intensity Therapeutics Inc. has a market capitalization of $8.68M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -298.6%.
Valuation Metrics
Market Cap
$8.68M
Enterprise Value
$4.85M
P/E Ratio
0.0x
PEG Ratio
-0.3x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+15.0%
Current Ratio
0.6x
Debt/Equity
39.2x
ROE
-298.6%
ROA
-123.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Intensity Therapeutics Inc. (INTS) Business Model
About Intensity Therapeutics Inc.
What They Do
Develops innovative cancer treatments using immunotherapy.
Business Model
The company focuses on creating proprietary immune-based drug products that enhance traditional cancer therapies. By integrating chemotherapy with immunotherapy through its DfuseRxSM technology platform, Intensity Therapeutics aims to stimulate a systemic immune response, thereby increasing the survival rates of cancer patients while reducing side effects.
Additional Information
Intensity Therapeutics is actively involved in clinical trials across various cancer types, including breast, colorectal, and liver cancers. The company's commitment to advancing medical research positions it as a significant player in the biotech industry, contributing to both scientific innovation and improved patient care.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
5
CEO
Mr. Lewis H. Bender M.A., M.B.A., M.S.
Country
United States
IPO Year
2022
Website
www.intensitytherapeutics.comIntensity Therapeutics Inc. (INTS) Latest News & Analysis
Latest News
Quick Summary
Intensity Therapeutics, Inc. reported that its therapy INT230-6 achieved complete responses in mice with Malignant Peripheral Nerve Sheath Tumor, advancing its immune-based cancer treatment development.
Why It Matters
Intensity Therapeutics' success with INT230-6 in achieving complete responses in MPNST models boosts its clinical prospects, potentially increasing stock value and investor interest in innovative cancer therapies.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Intensity Therapeutics reported that initial patients in the Phase 2 INVINCIBLE-4 study of INT230-6 showed high necrosis levels after 8 days, prior to starting standard care.
Why It Matters
High levels of necrosis in early patients suggest potential effectiveness for INT230-6, which could lead to favorable outcomes and increased investor interest in Intensity Therapeutics.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Intensity Therapeutics, Inc. plans to conduct an underwritten public offering of its common stock to support its late-stage development of immune-based cancer therapies.
Why It Matters
Intensity Therapeutics' public offering could dilute existing shares, affect stock price, and signal funding needs, impacting investor sentiment and future growth potential.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Intensity Therapeutics, Inc. announced a public offering of 6,675,000 shares at $0.30 each, aiming for gross proceeds of $2,002,500, before expenses.
Why It Matters
Intensity Therapeutics' public offering at $0.30 per share raises $2M, diluting existing shares and signaling cash needs, impacting stock valuation and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Intensity Therapeutics (Nasdaq: INTS) partners with Christine Handy to educate early-stage breast cancer patients about new immune-based treatment options.
Why It Matters
Intensity Therapeutics' collaboration with Christine Handy may enhance brand visibility and patient engagement, potentially driving demand for its cancer therapies and impacting stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Intensity Therapeutics (Nasdaq: INTS) will present a Trials in Progress poster on its Phase 3 INVINCIBLE-3 trial for INT230-6, targeting metastatic soft tissue sarcomas.
Why It Matters
The announcement of Intensity Therapeutics' Phase 3 trial for INT230-6 signifies potential advancements in cancer treatment, impacting stock performance and investor sentiment in biotech.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About INTS Stock
What is Intensity Therapeutics Inc.'s (INTS) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Intensity Therapeutics Inc. (INTS) has a median price target of $3.75. The highest price target is $5.00 and the lowest is $1.50.
Is INTS stock a good investment in 2026?
According to current analyst ratings, INTS has 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.33. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INTS stock?
Wall Street analysts predict INTS stock could reach $3.75 in the next 12 months. This represents a 1,026.1% increase from the current price of $0.33. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Intensity Therapeutics Inc.'s business model?
The company focuses on creating proprietary immune-based drug products that enhance traditional cancer therapies. By integrating chemotherapy with immunotherapy through its DfuseRxSM technology platform, Intensity Therapeutics aims to stimulate a systemic immune response, thereby increasing the survival rates of cancer patients while reducing side effects.
What is the highest forecasted price for INTS Intensity Therapeutics Inc.?
The highest price target for INTS is $5.00 from Swayampakula Ramakanth at HC Wainwright & Co., which represents a 1,401.5% increase from the current price of $0.33.
What is the lowest forecasted price for INTS Intensity Therapeutics Inc.?
The lowest price target for INTS is $1.50 from at , which represents a 350.5% increase from the current price of $0.33.
What is the overall INTS consensus from analysts for Intensity Therapeutics Inc.?
The overall analyst consensus for INTS is bullish. Out of 3 Wall Street analysts, 3 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $3.75.
How accurate are INTS stock price projections?
Stock price projections, including those for Intensity Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 13, 2025 11:50 PM UTC